Skip to main content
Premium Trial:

Request an Annual Quote

GenoLogics, Roswell Park Cancer Institute, LabVantage, ACD/Labs, SORD, NIH, Biobase

GenoLogics Closes Second Round of VC Funding
GenoLogics Life Sciences Software this week said it has completed a second round of financing led by OVP Venture Partners, along with Growth Works and Yaletown Venture Partners.
The company did not disclose the amount of funding that it raised in this round, which adds to $5 million in Series A financing led by OVP and Yaletown that the company raised last year [BioInform 02-07-05].
GenoLogics said the financing will enable it to “accelerate its systems biology market penetration strategy” and to advance development of its newly released Geneus software platform.

Roswell Park Cancer Institute Licenses LabVantage’s Sapphire LIMS and Biobanking Module
LabVantage said this week that the Roswell Park Cancer Institute has licensed its Sapphire Laboratory Information Management Suite, including its Sapphire BioBanking Module, for use in its translational research initiative.
RPCI will use Sapphire to integrate its biorepositories with its core research laboratories and clinical systems.
"The vision is to have Roswell biobanks act as the 'sanctioned pathway' between the hospital/clinic and research,” JoAnne Ruh, vice president of information technology for RPCI, said in a statement.
RPCI’s translational research initiative includes more than 12 core laboratories and four biobanks, including several from the University of Buffalo's Center of Excellence co-located at Roswell Park.

ACD/Labs, SORD to Build Database of ‘Hidden’ Chemical Reactions
The Selected Organic Reactions Database said this week that it will use technology from Advanced Chemistry Development as part of a project to capture chemical reaction information from unpublished theses and dissertations and make this data available in a searchable electronic format.
According to SORD, a chemical database developer based in Malden, the Netherlands, more than 50 million chemical reactions have been performed in academic research over the last 50 years, but only about 10 million of these reactions are available through major commercial chemical reaction databases.
“It is estimated that nearly half of the remaining 40 million reactions have been documented in unpublished theses and dissertations, leaving a rich source of lost, yet validated, chemical reaction data,” the company said in a statement.
The initial focus of SORD is one million chemical reactions that are considered relevant to pharmaceutical research. The database will be sold to pharmaceutical firms but will be free for academics who supply the company with their reaction data.
ACD/Labs will host the database, which is built upon the company’s ACD/Web Librarian technology, on its ChemFolder Enterprise platform. 

NIH Extends Subscription to Biobase's Proteome and Transfac Databases
Biobase said this week that the National Institutes of Health has extended its subscription to its Proteome and Transfac databases.
The Proteome database includes publicly available species-specific sequence information for 20 species, and the Transfac database contains annotated information for nearly 9,000 transcription factors and 18,000 transcription factor binding sites.
Financial terms of the agreement were not released.

Filed under